NEW YORK (GenomeWeb News) – ImaginAb, a Los Angeles-based developer of molecular imaging agents, has entered into an alliance with MacroGenics to develop companion imaging agents for an anti-cancer drug being developed by the Rockville, Md.-based biotech firm.

Under the deal announced today, ImaginAb will develop companion imaging agents for B7-H3, an immune regulator target for which MacroGenics is developing therapeutics. It also is developing a clinical imaging strategy based on a Macrogenics anti-CD3 antibody as a patient selection tool for ongoing clinical programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.